New Findings Suggest GLP-1 Medications May Increase Risk of Blinding Eye Diseases
Emerging research suggests that GLP-1 medications used for diabetes and weight loss may increase the risk of serious eye diseases, highlighting the importance of eye health monitoring.
Recent Research Links GLP-1 Drugs to Potential Eye Damage
A new study indicates that older adults taking GLP-1 receptor agonists, such as semaglutide and tirzepatide, may face a doubled risk of developing neovascular age-related macular degeneration (nAMD), an eye condition that can lead to vision loss. These medications, widely prescribed for type 2 diabetes and weight management, have previously been associated with rare eye complications.
The research analyzed health records of over 139,000 diabetic patients aged 66 and older in Ontario, Canada, during 2020-2023. It found that those on GLP-1 therapy for more than six months had a twofold increased risk of nAMD. Notably, the highest risk correlated with prolonged use, suggesting a possible cumulative effect.
While the absolute risk remains low—around 2 in 1,000 patients—health experts stress the importance of monitoring eye health in patients on these drugs. The findings emphasize the need for further studies to understand long-term safety and highlight the importance of regular eye examinations for patients on GLP-1 medications.
Focus on Semaglutide
Most prescriptions in the study involved semaglutide, marketed as Ozempic or Wegovy, predominantly prescribed for blood sugar control in diabetes and weight loss respectively. The study's senior researcher, Dr. Rajeev Muni, pointed out that the association does not prove causation but underscores a potential risk that warrants awareness.
Clinical Implications
Clinicians are advised to monitor visual symptoms in patients using GLP-1 drugs, especially older adults with diabetes. Patients should report any changes in vision promptly. Researchers caution that longer-term use may increase ocular risks, and more research is needed to explore causality.
Limitations and Future Directions
Experts acknowledge limitations, including potential surveillance bias and unmeasured confounding factors like smoking and obesity. Further investigations are needed to confirm these findings and evaluate the safety of other GLP-1 drugs.
As GLP-1 therapies continue to grow in popularity, awareness of possible eye-related side effects is crucial for ensuring comprehensive patient care.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
P2Y12 Inhibitors Outperform Aspirin for Preventing Heart Attack and Stroke in Coronary Artery Disease Patients
A new study shows that P2Y12 inhibitors like clopidogrel and ticagrelor may be more effective than aspirin in preventing heart attacks and strokes in coronary artery disease patients, with similar safety profiles.
Michigan Reports Second Measles Outbreak Amid Rising National Cases
Michigan reports its second measles outbreak of 2025 as the US reaches over 1,200 cases nationwide. The resurgence highlights the importance of vaccination to prevent severe complications and curb outbreaks.
Shorter Radiation Treatment Shows Improved Patient Experience but Similar Disease Control in Intermediate-Risk Prostate Cancer
A large phase III trial reveals that five-session stereotactic body radiation therapy improves quality of life for intermediate-risk prostate cancer patients, with similar disease control compared to longer courses.
Elevated Linoleic Acid Levels Associated with Reduced Risk of Heart Disease and Diabetes
Emerging research suggests that higher blood levels of linoleic acid, an omega-6 fatty acid, are linked to a lower risk of heart disease and type 2 diabetes, supporting dietary benefits of seed oils.